desloratadine
Sign in to saveDesloratadine, sold under the brand name Aerius among others, is a tricyclic H1 inverse agonist that is used to treat allergies. It is the major active metabolite of loratadine.
Key facts
- Drug.verifiedrevid
- 460777963
- Drug.image
- Desloratadine.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 222
- Drug.image2
- Desloratadine 3D ball-and-stick.png
- Drug.image_class2
- bg-transparent
- Drug.tradename
- Aerius, others
- Drug.MedlinePlus
- a602002
- Drug.DailyMedID
- Desloratadine
- Drug.pregnancy_AU
- B1
- Drug.routes_of_administration
- By mouth
- Drug.class
- Second-generation antihistamine
- Drug.ATC_prefix
- R06
- Drug.ATC_suffix
- AX27
- Drug.legal_AU
- S2
- Drug.legal_CA
- OTC
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
via Wikipedia infobox
Research
813 papers- Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review.Clinical pharmacokinetics · 2008
- Desloratadine: a nonsedating antihistamine.The Annals of pharmacotherapy · 2003
- Allergic Rhinitis: A Review.JAMA · 2024
- Desloratadine.Drugs · 2001
- Comparative Efficacy of Mometasone Nasal Spray Combined with Different Doses of Desloratadine, and Montelukast in Childhood Allergic Rhinitis: A Randomized Clinical Trial.Iranian journal of allergy, asthma, and immunology · 2024
via PubMed
Article
9 sectionsContents
- Medical uses
- Side effects
- Interactions
- Pharmacology
- Pharmacodynamics
- Pharmacokinetics
- Pharmacogenomics
- References
- Further reading
Desloratadine, sold under the brand name Aerius among others, is a tricyclic H1 inverse agonist that is used to treat allergies. It is the major active metabolite of loratadine.
It was patented in 1984 and came into medical use in 2001. It was brought to the market in the US by Schering Corporation, later named Schering-Plough.